How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

809 results for

Priapism

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

661. CSP #563

with PTSD will not be exclusionary (see below). Medications/Therapies: Current use of prazosin or other alpha-1 antagonist. Previous adequate trial of prazosin for PTSD. Subjects on trazodone will undergo a 2-week washout period before baseline assessment. (Combining prazosin and trazodone may increase risk of priapism). Sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra) will be not be permitted during the study dose titration period because of increased risk of hypotension in combination

2007 Clinical Trials

662. Pulmonary Hypertension, Hypoxia and Sickle Cell Disease

disease (electrophoretic HPLC documentation of SS, SC, Sb thalassemia or other major sickling phenotype such as SD, SO-Arab or SLepore is required). At least three weeks has elapsed since hospitalization for acute chest syndrome, pain crisis, infection or other complication of SCD. Absence of acute infection, pain crisis, or other acute complication of SCD. (Chronic SCD complications such as stuttering priapism, stable chronic pain and leg ulcers are not reasons for exclusion.) Inclusion criteria

2007 Clinical Trials

663. A Study To Assess If 10 mg Vardenafil (BAY38-9456) Taken Twice Daily For 6 Weeks Has An Effect On Bladder Function

of moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment In men: Clinically significant chronic haematological disease which may lead to priapism History of malignancy of any organ system within the past 5 years Bleeding disorder Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its

2007 Clinical Trials

664. Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin

or on assessment at the screening or baseline visits (defined as a decrease of 10 mm Hg or greater after standing for 2 minutes). Current antihypertensive treatment History of significant cardiac disease, including coronary artery disease Current use of phosphodiesterase type 5 inhibitors: sildenafil (ViagraTM), tadalafil (CialisTM), or vardenafil (LevitraTM) History of priapism (persistent and painful erection) Contacts and Locations Go to Information from the National Library of Medicine To learn more about

2007 Clinical Trials

665. A Placebo-Controlled Single-Dose Trial of Sildenafil in Schizophrenia

P45 3A4 (eg. phenytoin, carbamezapine, Phenobarbital, rifampin) Unstable medical disease Significant cardiac disease Bleeding disorder Peptic ulcer disease Hepatic impairment Moderate or greater renal impairment History of migraines Currently taking nitrates or alpha blockers Resting blood pressure < 90/50 or >140/90 mm. History of intolerance to PDE5 inhibitors History of inappropriate sexual behavior (eg, masturbation in public, stalking, assault) History of priapism Pregnant or lactating

2007 Clinical Trials

666. The Pharmacological Basis for the Increase in Visual Time Constants Induced by Single Oral Doses of Sildenafil

Bleeding disorders Peyronie's disease Priapism Subjects receiving prescribed medications Subjects with known visual abnormalities other than refractive errors, including retinitis pigmentosa, optic neuropathy Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number

2007 Clinical Trials

667. Sildenafil Therapy for Pulmonary Hypertension and Sickle Cell Disease

antihypertensive regimen for greater than or equal to 90 days and a stable dose for greater than or equal to 30 days. EXCLUSION CRITERIA: Current pregnancy or lactation. Any one of the following medical conditions: Stroke within the last six weeks. Diagnosis of pulmonary embolism within the last three months. History of retinal detachment or retinal hemorrhage in the last 6 months. Non-arteritic anterior ischemic optic neuropathy (NAION) in one or both eyes. History of sustained priapism requiring medical

2007 Clinical Trials

668. Vardenafil in Greenlight(TM) Laser Surgery of Benign Prostate Hypertrophy

degenerative retinal disorder History of previous Non-arteric Anterior Ischemic Optic Neuropathy (NAION) episode or unilateral vision impairment Any cardiovascular condition History of myocardial infarction, stroke or life-threatening arrhythmia within the prior 6 months Uncontrolled atrial fibrillation/flutter at screening Severe chronic or acute liver disease Chronic hematological disease which may lead to priapism Bleeding disorder Significant active peptic ulceration Resting hypotension History

2007 Clinical Trials

669. Efficacy Study of NH001 in Vegetative State & Minimally Conscious State Following a Traumatic Brain Injury

or any other drug that is known to produce priapism. Patients without a relative or legal guardian to consent to the study. Patients who, according to the investigator's opinion, are unlikely to be available for the required 180-day follow up evaluation. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study

2008 Clinical Trials

670. AScVS and/ or Prazosin for Scorpion Envenomation

on sweating, pulse rate, respiratory rate, blood pressure, CNS effects and presence of priapism. Computed doses were given according to clinical grading as intravenous bolus slowly. Drug: Antiscorpion venom serum(AScVS). AScVS therapy group If the score is 5 and if the patient belongs to pediatric group(>12-14): 1 vial AScVS as i.v. slow bolus after test dose If the score is 5 and if the patient is adult: 2 vials of AScVS as i.v. slow bolus after test dose. For injection, 1 vial will be dissolved in 10 ml (...) : 181 -200 and diast: 111-120 Or syst <100 Syst: > 200 and diast: >120 Or syst < 60 CNS effects 0 No sensory involvement Minimal tingling numbness around mouth Tingling, numbness around mouth and giddiness Altered sensorium, patient roudy Patient semiconscious Patient unconscious Priapism 2 Slight erection 3 Strong erection To obtain a composite score, grades for individual criterion will be added. Maximum score: 25 and minimum score: 0 Exclusion Criteria: (Any of the following) Composite score less

2008 Clinical Trials

671. Research Evaluating an Investigational Medication for Erectile Dysfunction

replacement therapy that has not been stable for at least 3 month; Initiation or change in dose of any alpha-blocker within 14 days prior to randomization; ED as a result of spinal cord injury or radical prostatectomy; Untreated hypogonadism or low serum total testosterone History of or predisposition to priapism; Any penile implant; Elevated PSA, other evidence of prostate cancer, or previous radical prostatectomy; History of any malignancy (except basal cell carcinoma or squamous cell carcinoma

2008 Clinical Trials

672. Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study)

antagonists or cytochrome P450 3A4 inhibitors (e.g., ketoconazole, itraconazole, erythromycin, saquinavir, cimetidine, or serum protease inhibitors for HIV) Retinitis pigmentosa, previous diagnosis of nonischemic optic neuropathy, untreated proliferative retinopathy, or unexplained visual disturbance Sickle cell anemia, multiple myeloma, leukemia, or penile deformities that increase the risk for priapism (e.g., angulation, cavernosal fibrosis, Peyronie's disease) Severe liver disease (aspartate

2008 Clinical Trials

673. Improvement of Erectile Dysfunction by Fluvastatin in Patients With Cardiovascular Risk Factors

, stroke, PTCA, vascular surgery) within 3 months before randomization clinical signs of heart failure or reduced left ventricular function current treatment with lipid lowering drugs insulin dependent diabetes mellitus or orally treated diabetes mellitus with a HbA1c-value >6.9% erectile dysfunction due to hormone disorders known malignant tumor known disposition to priapism patients with morphological changes of the penis (i.e. deviation) or penis-prosthesis current treatment with anticoagulants

2006 Clinical Trials

674. A Pilot Study of HSCT for Patients With High-Risk Hemoglobinopathy Using a Nonmyeloablative Preparative Regimen

per year for 3 years or more years or recurrent priapism, Impaired neuropsychological function and abnormal cerebral MRI scan, Stage I or II sickle lung disease, Sickle nephropathy (moderate or severe proteinuria or a glomerular filtration rate [GFR] 30-50% of the predicted normal value), Bilateral proliferative retinopathy and major visual impairment in at least one eye, Osteonecrosis of multiple joints with documented destructive changes, Requirement for chronic transfusions but with RBC

2007 Clinical Trials

675. Sildenafil to Increase Exercise Capacity in Individuals With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension

or greater than 300 mg/dl) Severe serum sodium abnormalities (serum sodium less than 130 mEq/L or greater than 150 mEq/L) Condition that may predispose participant to priapism (e.g., sickle cell anemia, multiple myeloma, leukemia) Retinitis pigmentosa Known or suspected idiopathic hypertrophic subaortic stenosis (IHSS) Low blood pressure (systolic blood pressure [SBP] less than 100 mm Hg or diastolic blood pressure [DBP] less than 50 mm Hg) Uncontrolled systemic high blood pressure (SBP greater than 180

2006 Clinical Trials

676. Cardiopulmonary Function Assessment and NO-Based Therapies for Patients With Hemolysis-Associated Pulmonary Hypertension

or the safety of the volunteer. For Stage II and III: Current pregnancy or lactation. Any of the following medical conditions Stroke within the last six weeks. History of sustained priapism requiring medical or surgical treatment, unless currently impotent or on exchange transfusion therapy, within two years. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information

2006 Clinical Trials

677. An Open Label, Dose Finding Trial of Viagra for the Treatment of Neuropathic Pain (in Diabetes Mellitus)

or tricyclic anti-depressants, however must be on a stable dose for 4 weeks prior to and during the study. Eligible patients must have a score of at least 40 on the VAS. Exclusion Criteria: Previous adverse reaction to viagra Blood pressure < 90/50 or > 170/100 unstable angina retinitis pigmentosa, myocardial infarction stroke or life-threatening arrhythmia within the last 6 months hemoglobulin A1c > 11 HIV infection history of priapism hepatic or renal failure pregnancy current or past use of nitrates

2005 Clinical Trials

678. Pilot Study of Terazosin in Treatment of Antidepressant Induced Excessive Sweating

, including coronary artery disease Current use of phosphodiesterase type 5 inhibitors: sildenafil (Viagra™), tadalafil (CialisTM), or vardenafil (LevitraTM) History of priapism (persistent and painful erection) Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number

2005 Clinical Trials

679. A Study of DA-8159 in Subjects With Erectile Dysfunction

of retinitis pigmentosa. Has a history of sickle cell disease, multiple myeloma, leukemia or any other disorders that may cause priapism. Has a history of significant psychiatric disorder. Has a history of central nervous system disorders such as stroke, transient ischemic attacks, or spinal cord injury. Has a history of drug abuse (alcohol, marijuana, cocaine, or opiates). Has a known sensitivity to drugs especially to phosphodiesterase type 5 inhibitors such as Viagra, Cialis or Levitra. Has used other

2006 Clinical Trials

680. The Therapy of Nebido as Mono or in Combination With PDE-5 Inhibitors in Hypogonadal Patients With Erectile Dysfunction

is uncontrolled (HbAlc level >10%) Epilepsy not adequately controlled by treatment Patients requiring fertility treatment Hypertension which is not adequately controlled on therapy Clinically significant chronic hematological disease which may lead to priapism such as sickle cell anemia, multiple myeloma or leukemia Hypersensitivity to PDE-5 inhibitors Concomitant Medication: Nitrites or Nitric oxide donors Anti-androgens anti-coagulants, with the exception of anti-platelet agents Any of potent inhibitors

2007 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>